The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
ALK Tyrosine Kinase Inhibitors (ALK-TKIs)-Global Market Insights and Sales Trends 2024
Synopsis
Anaplastic Lymphoma Kinase (ALK) gene, as a tyrosine kinase closely related to tumors, can be activated by translocation or mutation. Abnormal expression such as gene mutation, rearrangement and amplification can activate cell signal transduction in the body. Pathway, which regulates the growth, differentiation and migration of tumors. Tyrosine kinases are kinases that enzymatically catalyze the transfer of gamma phosphate groups from adenosine triphosphate to target proteins. They can catalyze the phosphorylation of protein tyrosine residues on a variety of substrates, and play an important role in cell growth, proliferation, and differentiation. The main oncology indications for tyrosine kinase inhibitors (TKI) include solid tumors and leukemia.
The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in various end use industries. The expanding demands from the Leukemia, Solid Tumor, Lung Cancer and Others, are propelling ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market. Crizotinib, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alectinib segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, driven by demand from China, the second largest economy with some signs of stabilising, the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) covered in this report include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc.
The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, Segment by Type:
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, by Application
Leukemia
Solid Tumor
Lung Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Anaplastic Lymphoma Kinase (ALK) gene, as a tyrosine kinase closely related to tumors, can be activated by translocation or mutation. Abnormal expression such as gene mutation, rearrangement and amplification can activate cell signal transduction in the body. Pathway, which regulates the growth, differentiation and migration of tumors. Tyrosine kinases are kinases that enzymatically catalyze the transfer of gamma phosphate groups from adenosine triphosphate to target proteins. They can catalyze the phosphorylation of protein tyrosine residues on a variety of substrates, and play an important role in cell growth, proliferation, and differentiation. The main oncology indications for tyrosine kinase inhibitors (TKI) include solid tumors and leukemia.
The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) in various end use industries. The expanding demands from the Leukemia, Solid Tumor, Lung Cancer and Others, are propelling ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market. Crizotinib, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alectinib segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, driven by demand from China, the second largest economy with some signs of stabilising, the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for ALK Tyrosine Kinase Inhibitors (ALK-TKIs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) covered in this report include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc.
The global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, Segment by Type:
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market, by Application
Leukemia
Solid Tumor
Lung Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of ALK Tyrosine Kinase Inhibitors (ALK-TKIs)
1.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Overview
1.1.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Product Scope
1.1.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Status and Outlook
1.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Region (2018-2029)
1.4 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Historic Market Size by Region (2018-2023)
1.5 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
1.6.1 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
1.6.2 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
1.6.3 Asia-Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
1.6.4 Latin America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
1.6.5 Middle East & Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size (2018-2029)
2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market by Type
2.1 Introduction
2.1.1 Crizotinib
2.1.2 Alectinib
2.1.3 Ceritinib
2.1.4 Brigatinib
2.1.5 Lorlatinib
2.1.6 Ensartinib
2.1.7 CT-707
2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Historic Market Size by Type (2018-2023)
2.2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Type (2018-2029)
3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Overview by Application
3.1 Introduction
3.1.1 Leukemia
3.1.2 Solid Tumor
3.1.3 Lung Cancer
3.1.4 Others
3.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Historic Market Size by Application (2018-2023)
3.2.2 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue Breakdown by Application (2018-2029)
4 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Competition Analysis by Players
4.1 Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in ALK Tyrosine Kinase Inhibitors (ALK-TKIs) as of 2022)
4.3 Date of Key Players Enter into ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market
4.4 Global Top Players ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Headquarters and Area Served
4.5 Key Players ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Product Solution and Service
4.6 Competitive Status
4.6.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.1.4 Pfizer ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Nuvartis
5.2.1 Nuvartis Profile
5.2.2 Nuvartis Main Business
5.2.3 Nuvartis ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.2.4 Nuvartis ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.2.5 Nuvartis Recent Developments
5.3 Takeda
5.3.1 Takeda Profile
5.3.2 Takeda Main Business
5.3.3 Takeda ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.3.4 Takeda ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.3.5 Betta Pharma Recent Developments
5.4 Betta Pharma
5.4.1 Betta Pharma Profile
5.4.2 Betta Pharma Main Business
5.4.3 Betta Pharma ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.4.4 Betta Pharma ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.4.5 Betta Pharma Recent Developments
5.5 Shouyao Holding
5.5.1 Shouyao Holding Profile
5.5.2 Shouyao Holding Main Business
5.5.3 Shouyao Holding ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.5.4 Shouyao Holding ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.5.5 Shouyao Holding Recent Developments
5.6 Chugai Pharmaceutical Co
5.6.1 Chugai Pharmaceutical Co Profile
5.6.2 Chugai Pharmaceutical Co Main Business
5.6.3 Chugai Pharmaceutical Co ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Products, Services and Solutions
5.6.4 Chugai Pharmaceutical Co ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue (US$ Million) & (2018-2023)
5.6.5 Chugai Pharmaceutical Co Recent Developments
6 North America
6.1 North America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Dynamics
11.1 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Industry Trends
11.2 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Drivers
11.3 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Challenges
11.4 ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
